Is Moderna Stock A Buy Following Skin Cancer Vaccine Progress?
- Thursday, December 15, 2022, 7:13
- Market
- Add a comment
Moderna stock rallied by close to 20% in Tuesday’s trading, after it announced positive results from mid-stage trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck.
About the Author
admin123 has written 23527 stories on this site.
